1. Iengar P, Venkatraman P (2025). Using the reactome graph database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks. Computational Biology and Chemistry.

2. Jalali R, Ghosh S, Chatterjee A, Goswami S, Shah N, Dutta D, Krishna U, Gupta T, Goda JS (2025). High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial. Neuro Oncology.

Book/Manual
Samantaray S, Patil S, Patra P, Mohanty S, Swain S, Panda P, Budukh A, Chaturvedi P (2025). Identification and management of oral potentially malignant disorders and cancer: Manual for health workers of Odisha state. Tata Memorial Centre, Mumbai. (ISBN: 978-93-82963-79-0)

ChEMBL is a manually curated database of bioactive molecules with drug-like properties. It brings together chemical, bioactivity and genomic data to aid the translation of genomic information into effective new drugs.

Hegde S, Giotti B, Soong BY, Halasz L, Le Berichel J, Schaefer MM, Kloeckner B, Mattiuz R, Park MD, Magen A, Marks A, Belabed M, Hamon P, Chin T, Troncoso L, Lee JJ, Fan K, Ahimovic D, Bale MJ, Nie K, Chung G, D'souza D, Angeliadis K, Kim-Schulze S, Flores RM, Kaufman AJ, Ginhoux F, Buenrostro JD, Josefowicz SZ, Tsankov AM, Marron TU, Ma S, Brown BD, Merad M (2025). Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours. Nature.

In 2014, Pembrolizumab (Keytruda) became the first PD-1-targeting immune checkpoint inhibitor approved by FDA.

2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)